Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22356082 | 0.95 | POLB (0.56) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL5053830 | 0.95 | POLB (0.56) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL7874672 | 0.84 | FKBP1A (0.64) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL1775248 | 0.84 | FKBP1A (0.64) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL14426630 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL12566180 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL3061683 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL7451535 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL5965365 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 | |
| SCHEMBL70309 | 0.84 | FKBP1A (0.57) | FKBP1APOLBPEPDXPNPEP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016199761-A1 | DIFLUOROMETHYLENE COMPOUNDS | 石原産業株式会社 | 2016-12-15 | — | — | WO | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | FKBP1A 543/4885POLB 3329/4885PEPD 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.